THE MICRODOSE CONCEPT Presenter: Professor Colin Garner BPharm PhD DSc FRCPath CEO, Xceleron Ltd, York, UK ® Xceleron Ltd – all rights reserved ©2004.

Slides:

Advertisements

Similar presentations

Combination of accelerator mass spectrometry (AMS) with positron emission tomography (PET) in human microdosing studies M. Simpson1, G. Lappin2, C. Wagner3,

Advertisements

The Drug Discovery Process

Phase 0 Imaging Studies From Regulations to Reality: Obtaining and Holding an IND at Your Institution Karen A. Kurdziel, MD Virginia Commonwealth University,

Xceleron - all rights reserved ©2009 Graham Lappin Chief Scientific Officer Xceleron Inc.

Dr. Kumud More ICRI, Mumbai 15/04/10

Regulatory Framework Leigh Shaw, Director.

Drug Research and Development (R&D) Karol Godwin DVM.

Microdosing: Past and Future (an introduction to microdosing and where it’s heading) Dr Graham Lappin Chief Scientific Officer Xceleron Inc Insert your.

Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA

1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.

MGTADM 022 T 03 F 1 “microdosing” in Google: first 4 hits Gesponsorde Koppelingen U.S. Microdosing Studies FDA Exploratory-IND.

JMV 1843 pharmacological profile

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.

Nanotechnology in Drug Discovery- Development and Delivery

1 University of Minnesota Life Science Presents: Ultra Sensitive Technology: Monitoring Bone Health Susanta K Hui, PhD, DABR Assistant Professor, Therapeutic.

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

INTRODUCTION Traditionally, absolute bioavailability (ABA) has been determined using a crossover study design, requiring administration of an IV dose expected.

Stefan Franzén Introduction to clinical trials.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

NMF 3/6/03 Susan Galbraith, MB BChir PhD Vice President Clinical Discovery Oncology & Immunology Phase 0 Trials Why aren’t they more widely used by industry?

Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.

1 Drug Safety, Animal Use, and Critical Path Opportunities FDA Science Board Advisory Committee Meeting March 31, 2005 Sadhana Dhruvakumar Director, Medical.

1 FDA Survey of Lead in Pharmaceuticals John F. Kauffman, PhD R&D Team Leader CDER, Division of Pharmaceutical Analysis ACPS-CP Meeting July 22,2008.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.

Stages of drug development

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Dosimetry of Beryllium in an Animal Model by Accelerator Mass Spectrometry (AMS) Marina Chiarappa-Zucca R.C. Finkel J.E. McAninch R.E. Martinelli K.W.

Obtaining and Negotiatiing a Position in Industry/Biotech Roy G. Smith Ph.D. Director, Huffington Center on Aging Professor, Department of Molecular and.

Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.

Stefan Franzén Introduction to clinical trials.

Investigational New Drug Application (IND)

Phase 1 Clinical Studies First-In-Human (FIH) Pharmacologically-Guided Dose Escalation Jerry M. Collins, Ph.D. Developmental Therapeutics Program Division.

Exploratory IND Studies

Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.

Phase 0/eIND Clinical Trial Nimita Dave, M.S. April 28, 2011.

CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Concepts and Applications of Pharmacokinetics

Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Departments of Dermatology & Radiation Oncology University of Rochester Medical.

1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

Proteomics Session 1 Introduction. Some basic concepts in biology and biochemistry.

Chapter 3 Average Atomic Mass. Section 3 Counting Atoms Relative Atomic Masses The standard used by scientists to compare units of atomic mass is the.

Consider Incorporating Respiratory Safety Pharmacology Measurements into Your Next Repeat Dose Toxicology Study September 14, 2012 Jeff Tepper, PhD, DABT.

A Literature Review to Investigate if Blood Compatibility Tests are a Necessary Procedure in the Pharmaceutical Industry to Predict Adverse Toxicology.

1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.

Radioimmuno assay. Immunoassay reactions may be competitive or non-competitive  Competitive labeled known and patient unknown are added to reaction and.

Drug Regulation, Development, Names, and Information Chapter 3 Copyright (c) 2004 Elsevier Inc. All rights reserved.

Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

PRECLINICAL PHARMACOLOGY & TOXICOLOGY OF ANTI-NEOPLASTIC AGENTS  THE NCI PERSPECTIVE Joseph E. Tomaszewski, Ph.D. Toxicology & Pharmacology Branch.

Phases of Therapeutic Development by Virinder Nohria, MD, PhD Presented at ASENT Annual Meeting Symposium on Neurotherapeutics Arlington, VA March 6, 2008.

Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase 3 Dose Selection (Musser et.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,

The process of drug development. Drug development 0,8 – 1 mld. USD.

The immune response CRO

The Stages of a Clinical Trial

5 Pharmacodynamics.

Pre-Investigational New Drug (pre-IND) Meeting with FDA

Benefits of US EFS: A Clinical Perspective

Early Feasibility in the USA –An Academic View

Sophie Lancelot, Luc Zimmer Trends in Pharmacological Sciences

5 Pharmacodynamics.

Clinical Pharmacokinetics

Dose setting for a Phase I Clinical Study

Presentation transcript:

THE MICRODOSE CONCEPT Presenter: Professor Colin Garner BPharm PhD DSc FRCPath CEO, Xceleron Ltd, York, UK ® Xceleron Ltd – all rights reserved ©2004

A new product development tool kit ….is urgently needed to improve predictability and efficiency along the critical path ® Xceleron Ltd – all rights reserved ©2004

SUB-OPTIMAL PHARMACOKINETICS IS A COMMON REASON FOR DRUG FAILURE ® Xceleron Ltd – all rights reserved ©2004 OUR INDUSTRY CONTACTS STATE THAT HUMAN ADME/PK PREDICTION IS INCORRECT IN APPROXIMATELY 25-30% OF CASES!

THE AMS TECHNOLOGY ® Xceleron Ltd – all rights reserved ©2004

AMS counts atoms and not radioactivity For ease of understanding for biomedical researchers AMS data is expressed as DPMs AMS is the most sensitive analytical technique ever developed and has been used to measure drugs, metabolites, proteins, peptides and endogenous molecules ® Xceleron Ltd – all rights reserved ©2004 Carbon-14 = isotope of choice for AMS drug analysis Many other elemental isotopes can be analysed

Accelerator Mass Spectrometry (AMS) detects molecules at unprecedented levels of sensitivity g g g g g Liquid scintillation counting Competitor immunoassay Mass Spectrometry Accelerator Mass Spectrometry nanograms picograms femtograms attograms zeptograms Only AMS has the necessary analytical sensitivity for microdosing and ultralow label studies ® Xceleron Ltd – all rights reserved ©2004

RADIOACTIVE DOSES Typical radioactive dose in a conventional study = 80 to 100 µCi per person Typical radioactive dose in an AMS study = 100 nCi per person The average person contains ca 400 nCi naturally-occurring 14 C The average person contains ca 50 nCi naturally-occurring 40 K A banana contains about 1 nCi 40 K ® Xceleron Ltd – all rights reserved ©2004 FDA Regulatory issue ‘Is there a de minimis level of 14 C that can be administered to humans in the USA without animal dosimetry studies under 21CFRPart361?’

HUMAN MICRODOSING – GOING FROM LAB BENCH TO CLINIC IN FOUR MONTHS ® Xceleron Ltd – all rights reserved ©2004

WHAT IS MICRODOSING? Designed to obtain early human ADME/PK with minimal preclinical toxicology No pharmacological/toxic effect should be manifest No human safety/efficacy information obtained Requires radioisotopes and ultrasensitive analytical procedures eg AMS or PET ® Xceleron Ltd – all rights reserved ©2004

EARLY CANDIDATE SELECTION CURRENT PROBLEM Although many improvements in recent years, still limited information from in vitro and animal models to predict events in humans Lack of predictivity of allometric scaling? ® Xceleron Ltd – all rights reserved ©2004

CURRENT REGULATORY POSITION ® Xceleron Ltd – all rights reserved ©2004 FDA regulatory issue ‘Is the Agency minded to update 21CFR361 to include NCEs?’

WHAT IS A MICRODOSE? EMEA definition 1/100th of pharmacological dose based on animal data / in vitro systems OR a dose in or below the low microgram range but not to exceed 100 micrograms ® Xceleron Ltd – all rights reserved ©2004 FDA Regulatory issue ‘Can 21CFRPart361 include specific mention of microdosing as per the EMEA definition?’

TOXICOLOGY PACKAGE FOR MICRODOSE STUDIES Single dose 7 day acute study in rat with histopathology 3 male, 3 female, iv & route of human exposure Either 100 or 1000-fold safety factor 48 h, CVS in dog, 2 male 2 female, iv, telemetered or ECG, 100-fold safety factor Ames test - abridged protocol or OECD Abridged human lymphocyte chrom abs – abridged protocol or OECD In vitro metabolism studies rat and human plus plasma protein binding ® Xceleron Ltd – all rights reserved ©2004 FDA regulatory issue ‘What preclinical toxicology package could be used to support microdosing studies under 21CFR Part 361?’

® Xceleron Ltd – all rights reserved ©2004 REGULATORY ISSUES TO BE CONSIDERED Can microdose studies on NCEs be covered by 21CFR Part361 Is AMS a technology that meets the Critical Path initiative of accelerating drug development? Are there scientific/regulatory reasons why AMS should not be used for all human volunteer radioactive studies (ALARA or ALARP) Are microdosing studies safer for FIH than current Phase I procedures? NEXT STEPS?